Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences, Inc. President and CEO Paul Badawi sold 29,244 shares of common stock at a weighted average price of $3.70 per share. According to the disclosure, these shares were sold to cover his tax liability arising from the vesting of restricted stock units.
The shares were sold in multiple transactions at prices ranging from $3.63 to $3.85. After this tax-related sale, Badawi directly holds 5,544,983 shares of common stock and has an additional 606,173 shares that will be received upon future vesting and settlement of RSUs.
Sight Sciences, Inc. announced that the U.S. District Court for the District of Delaware issued an order preserving a jury’s verdict that Alcon willfully infringed three Sight Sciences glaucoma patents. The order awards $34 million in past monetary damages, plus supplemental damages and interest, and grants an ongoing 10% royalty on Hydrus Microstent revenue through November 10, 2028, when the last asserted patent expires. A final judgment will be entered after supplemental damages and pre-judgment interest are calculated and remains subject to appeal by Alcon. Parallel ex parte reexaminations at the USPTO could affect Sight Sciences’ ability to collect if adverse outcomes become final before the litigation is finally resolved in the company’s favor. Sight Sciences expects to record a $5.4 million success fee payable to its litigation counsel in operating expenses, which it plans to exclude from non-GAAP adjusted operating expenses.
Sight Sciences, Inc. is an eyecare technology company focused on interventional treatments for glaucoma and dry eye disease. It develops devices designed to restore the eye’s natural drainage and tear-film function, targeting large but under-served markets.
The company’s interventional glaucoma business centers on the OMNI Surgical System and the SION Surgical Instrument, which enable minimally invasive glaucoma surgery in both cataract-combination and standalone procedures. For dry eye, its TearCare system delivers controlled heat and manual gland expression to treat meibomian gland disease, supported by randomized clinical trials such as OLYMPIA and SAHARA and health-economic studies showing potential cost savings versus prescription drops.
Sight Sciences emphasizes clinical evidence, reimbursement access, and specialized sales teams in the U.S. and select international markets. As of June 30, 2025, non-affiliate market value was about $153.6 million, and 54,005,984 common shares were outstanding as of February 26, 2026.
Sight Sciences reported mixed 2025 results with improving profitability trends and issued 2026 guidance. Full-year 2025 revenue was $77.4 million, down 3% from 2024, as Interventional Glaucoma revenue held flat at $75.7 million while Interventional Dry Eye fell to $1.6 million.
Fourth-quarter 2025 revenue was $20.4 million, up 7%, with total gross margin at 87%. Full-year gross margin was 86%. Operating expenses fell 13% to $103.8 million and net loss narrowed to $38.4 million, or $0.74 per share, from $51.5 million.
Cash and cash equivalents were $92.0 million and long-term debt $40.0 million as of December 31, 2025, after $28.4 million of cash use in 2025. For 2026, the company guides revenue to $82–$88 million and adjusted operating expenses to $93–$96 million.
Sight Sciences, Inc. Chief Technology Officer David Badawi exercised previously granted stock options for 21,270 shares of common stock at $0.23 per share. These options were awarded under the company’s equity incentive plan and fully vested by January 1, 2020.
Following this option exercise, Badawi directly holds a total of 1,998,458 common share equivalents, consisting of 1,795,520 shares of common stock and 202,938 shares that will be received upon the future vesting and settlement of restricted stock units.
Sight Sciences, Inc. disclosed that Chief Technology Officer and director David Badawi received a grant of 64,915 restricted stock units (RSUs) on February 3, 2026 under the company’s 2021 Incentive Award Plan. The grant value is based on $420,000 divided by the closing price of Sight Sciences common stock on the grant date.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on his continued service. After this grant, Badawi beneficially owns 1,977,188 common shares, including 1,774,250 shares and 202,938 unvested RSUs that may settle into additional shares over time.